PLX
Protalix BioTherapeutics, Inc.
Key Financials
Gross Profit
$4.0M
↑ 400.7%
Operating Income
$-5500000
↓ 240.4%
Revenue
$52.7M
↓ 1.2%
Net Income
$-6604000
↓ 325.2%
EPS (Diluted)
$-0.08
↓ 300.0%
Total Liabilities
$34.1M
↑ 12.9%
Cash & Equivalents
$14.7M
↓ 25.7%
Shareholders' Equity
$48.2M
↑ 11.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| S-8 | 8/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PLX |
| Company Name | Protalix BioTherapeutics, Inc. |
| CIK | 1006281 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 201-696-9345 |